NASDAQ · LXEO
Lexeo Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LXEO: Nov 4, 2026
Lexeo Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.33. The reported EPS for the same quarter last year was $-0.33.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.33 | $-0.31 | $-0.35 | 4 |
| Dec 2026 | $-0.34 | $-0.31 | $-0.40 | 4 |
| Mar 2027 | $-0.32 | $-0.32 | $-0.32 | 2 |
| Jun 2027 | $-0.34 | $-0.33 | $-0.34 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · BNK Invest · Fintel- MarketBeat · Oct 25, 10:02 AM EDTLexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 ReadoutPharma Frenzy: Volatility Ignites Biotech SectorLexeo Therapeutics (NASDAQ:LXEO) outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich’s ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy during the Chardan Healthcar
- MarketBeat · Oct 24, 3:02 AM EDTLexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene TherapyPharma Frenzy: Volatility Ignites Biotech SectorLexeo Therapeutics (NASDAQ:LXEO) outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, or ACM, ahead of an expected clinical and regulatory updat
- RTTNews · Sep 22, 10:07 AM EDTLexeo Expands Friedreich Ataxia Pipeline Through Mantle Deal, New Collaborations(RTTNews) – Lexeo Therapeutics, Inc. (LXEO) is strengthening its position in Friedreich ataxia through the planned acquisition of Mantle Therapeutics and the launch of patients living with the rare genetic disease.
- RTTNews · Sep 22, 7:31 AM EDTLexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich Ataxia(RTTNews) – Lexeo Therapeutics, Inc. (LXEO), a clinical stage company, announced Tuesday a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire private clinical stage company Mantle Therapeut
- RTTNews · Aug 12, 8:41 AM EDTLexeo Advances LX2006 Pivotal Program; SUNRISE-FA 2 Data Expected In 2H27(RTTNews) – Lexeo Therapeutics, Inc. (LXEO), a clinical-stage genetic medicine company focused on developing treatments for cardiovascular diseases, has reported its second-quarter 2026 financial results and provided business updates, highlighting the initiation of the pivotal SU
- RTTNews · Aug 5, 10:52 AM EDTLexeo's LX2020 Secures FDA RMAT Tag For PKP2-Associated Arrhythmogenic Cardiomyopathy(RTTNews) – Lexeo Therapeutics (LXEO) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM).
- RTTNews · Jun 15, 9:12 AM EDTPre-Market Movers: BYAH, LXEO, ELTX Swing Big(RTTNews) – Biotech companies are seeing significant pre-market activity this Monday.
- BNK Invest · Jan 9, 3:47 PM ESTNoteworthy Friday Option Activity: CC, IBM, LXEOAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Chemours Co (Symbol: CC), where a total of 9,406 contracts have traded so far, representing approximately 940,600 underlying shares. That amounts to about 42.5% of CC's
- RTTNews · Jan 8, 8:19 AM ESTLexeo Therapeutics Partners With JNJ To Investigate Localized Cardiac Delivery Of Gene Therapy(RTTNews) – Lexeo Therapeutics, Inc. (LXEO), Thursday announced a research collaboration with Johnson & Johnson (JNJ) to investigate localized cardiac delivery of gene therapy.
- Fintel · Dec 18, 7:03 AM ESTRaymond James Initiates Coverage of Lexeo Therapeutics (LXEO) with Strong Buy RecommendationFintel reports that on December 18, 2025, Raymond James initiated coverage of Lexeo Therapeutics (NasdaqGM:LXEO) with a Strong Buy recommendation. Analyst Price Forecast Suggests 117.21% Upside
- RTTNews · Dec 17, 11:15 PM ESTBiotech Momentum Carries After-Hours Trading Gains(RTTNews) – Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by investor sentiment and sector momentum.
- Fintel · Dec 11, 11:35 AM ESTChardan Capital Maintains Lexeo Therapeutics (LXEO) Buy RecommendationFintel reports that on December 11, 2025, Chardan Capital maintained coverage of Lexeo Therapeutics (NasdaqGM:LXEO) with a Buy recommendation. Analyst Price Forecast Suggests 103.37% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Lexeo Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.